Suppr超能文献

150毫克组织型纤溶酶原激活剂两小时输注治疗急性心肌梗死的疗效。

Efficacy of a two-hour infusion of 150-mg tissue plasminogen activator in acute myocardial infarction.

作者信息

Lew A S, Cercek B, Lewis B S, Hod H, Shah P K, Ganz W

机构信息

Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California 90048.

出版信息

Am J Cardiol. 1987 Dec 1;60(16):1225-9. doi: 10.1016/0002-9149(87)90599-6.

Abstract

Forty-two patients with acute myocardial infarction received 150-mg recombinant human tissue-type plasminogen activator (rt-PA) at 2.3 +/- 1.2 hours after the onset of chest pain. After a 40 U/kg bolus of heparin, rt-PA was given as a 10-mg bolus followed by a 2-hour continuous infusion of 90 mg in the first hour and 50 mg in the second hour. Nonangiographic signs of reperfusion occurred during treatment (41 +/- 21 minutes) in 35 patients and in 1 other patient about 30 minutes after rt-PA. Three patients had discordant nonangiographic signs of reperfusion, 2 patients had no evidence of reperfusion and 1 patient in cardiogenic shock died before completion of the rt-PA infusion and before reperfusion status could be ascertained. Clinical signs of early reocclusion occurred in 4 of the 36 patients with evidence of reperfusion, 3 of whom were retreated with rt-PA with clinical success in 2. Coronary angiography 10 +/- 8 hours later revealed a patent artery of infarction in 35 patients: 32 with nonangiographic signs of sustained reperfusion, both patients with successfully treated reocclusion and 1 of 3 patients with discordant signs of reperfusion. Angiography revealed evidence of partial reperfusion in the remaining 2 patients with discordant signs, and an occluded artery was found in both patients without any evidence of reperfusion and in both patients with clinical signs of persistent reocclusion. Hemorrhagic complications occurred in 9 patients, 7 were related to procedural trauma and 2 patients required a blood transfusion. Four patients died, each of a cardiac cause: 3 in hospital and 1 at home.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

42例急性心肌梗死患者在胸痛发作后2.3±1.2小时接受150毫克重组人组织型纤溶酶原激活剂(rt-PA)治疗。在给予40 U/kg肝素推注后,rt-PA先静脉推注10毫克,随后在第1小时持续输注90毫克,第2小时持续输注50毫克。35例患者在治疗期间(41±21分钟)出现非血管造影再灌注征象,另1例患者在rt-PA给药后约30分钟出现。3例患者出现不一致的非血管造影再灌注征象,2例患者无再灌注证据,1例心源性休克患者在rt-PA输注完成前及再灌注状态确定前死亡。36例有再灌注证据的患者中,4例出现早期再闭塞临床征象,其中3例再次接受rt-PA治疗,2例临床成功。10±8小时后的冠状动脉造影显示,35例患者梗死相关动脉通畅:32例有持续再灌注的非血管造影征象,2例再闭塞治疗成功的患者以及3例不一致征象患者中的1例。血管造影显示,其余2例不一致征象患者有部分再灌注证据,2例无再灌注证据的患者以及2例有持续再闭塞临床征象的患者梗死相关动脉均闭塞。9例患者出现出血并发症,7例与操作创伤有关,2例患者需要输血。4例患者死亡,均为心脏原因:3例在医院死亡,1例在家中死亡。(摘要截断于250字)

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验